IP Library Granted Patent US 10,577,598
Granted Patent B2
US 10,577,598 · App. 15/607,300 · Granted Mar 3, 2020

Display library process

Inventors: Robert Charles Ladner (Ijamsville, MD); Shannon Hogan (Arlington, MA); Kristin L. Rookey (Lebanon, NH)
Assignee: Dyax Corp.
C12N15/1037B03C1/01B03C1/288G01N33/56983C40B30/04G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,598
App. No.
15/607,300
Granted
Mar 3, 2020
Kind
B2
Abstract

Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.

Claims (26)

1. A method of selecting a binding protein that binds to a target, the method comprising:

(a) contacting a first plurality of diverse phage particles to a target to form phage-target complexes, wherein each phage particle of the first plurality displays a heterologous protein component on its surface and each phage includes a nucleic acid encoding the heterologous protein component, and wherein each phage-target complex comprises a phage from the first plurality, the heterologous protein component displayed on which binds the target;

(b) separating the phage-target complexes from unbound phage particles;

(c) contacting the separated phage-target complexes with a ligand under conditions wherein the ligand causes dissociation of one or more of the phage-target complexes to release free phage particles;

(d) isolating the free phage particles, wherein the heterologous protein components displayed on the surface of the free phage particles are binding proteins to the target; and

(e) infecting host cells with the isolated free phage particles from step (d) to produce a second plurality of phage particles,

wherein step (e) is performed in the presence of the target.

2. The method of claim 1 , wherein step (e) comprises: maintaining the host cells under conditions whereby the free phage particles are replicated, thereby producing the second plurality of phage particles.

3. The method of claim 1 , further comprising repeating steps (a)-(e) for one or more cycles.

4. The method of claim 1 , wherein the ligand binds to the target.

5. The method of claim 4 , wherein the target is a protein and the ligand binds to an epitope of the target.

6. The method of claim 5 , wherein the concentration of the ligand in step (c) is greater than its dissociation constant (Kd) for the target.

7. The method of claim 1 , wherein the ligand binds to the phage.

8. The method of claim 7 , wherein the target is a protein and the ligand is structurally homologous to at least a segment of the target.

9. The method of claim 1 , wherein step (e) further comprises removing the ligand from a culture media where the infected host cells are maintained.

10. The method of claim 1 , wherein the target is immobilized to a support.

11. The method of claim 10 , wherein the target is immobilized to the support via a non-covalent interaction.

12. The method of claim 10 , wherein the target is covalently immobilized to the support.

13. The method of claim 1 , further comprising recovering the second plurality of diverse phage produced in step (e).

14. The method of claim 1 , wherein during step (e), fewer than 5000 progeny phage are produced for each phage particle that infects one of the host cells.

15. The method of claim 1 , wherein step (e) is completed in less than 4 hours.

16. The method of claim 2 , wherein during step (e), the host cells divide less than seven times.

17. The method of claim 2 , wherein the step (e) involves a change in temperature.

18. The method of claim 1 , wherein each phage of the first plurality comprises genes sufficient for phage replication in a host cell.

19. The method of claim 1 , wherein each phage of the first plurality comprises a phagemid, and wherein step (e) is performed in the presence of helper phages.

20. The method of claim 1 , wherein the host cells are cells of a mutator strain.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2018
From: LADNER, ROBERT C.; HOGAN, SHANNON; ROOKEY, KRISTIN
To: DYAX CORP.
Reel/Frame 047521/0795 →
Continuity (4)
Division 14048526 · Oct 8, 2013
Division 10656350 · Sep 5, 2003
Provisional Application 60408624 · Sep 5, 2002
Related Publication 20170355980A1 · Dec 14, 2017